[1] de Las Rivas M, Lira-Navarrete E, Gerken TA, et al. Polypeptide GalNAc-Ts: from redundancy to specificity[J]. Current Opinion in Structural Biology, 2019, 56:87~96. [2] Mao Y, Zhang Y, Fan S, et al. GALNT6 promotes tumorigenicity and metastasis of breast cancer cell via β-catenin/MUC1-C signaling pathway[J]. International Journal of Biological Sciences, 2019,15(1):169~182. [3] Deng B, Tarhan Y E, Ueda K, et al. Critical role of estrogen receptor alpha O-glycosylation by N-acetylgalactosaminyltransferase 6 (GALNT6) in its nuclear localization in breast cancer cells[J]. Neoplasia, 2018,20(10):1038~1044. [4] Kimura R, Yoshimaru T, Matsushita Y, et al. The GALNT6LGALS3BP axis promotes breast cancer cell growth[J]. Int Oncol, 2020,56(2):581~595. [5] Zuo T, Shan J, Liu Y, et al. EFEMP2 mediates GALNT14-dependent breast cancer cell invasion[J]. Translational oncology, 2018, 11(2):346~352. [6] Kang N, Zhou J, Xu J, et al. EFEMP2 inhibits breast cancer invasion and metastasis in vitro and in vivo[J].OncoTargets and Therapy,2019,12:8915~8933. [7] Yao B, Wang J, Qu S, et al. Upregulated osterix promotes invasion and bone metastasis and predicts for a poor prognosis in breast cancer[J].Cell Death & Disease,2019,10(1):28. [8] Wu J, Chen X, Bao Q, et al. Osterix decreases the chemosensitivity of breast cancer cells by upregulating GALNT14[J]. Cellular Physiology & Biochemistry, 2017, 44(3):998~1010. [9] Shan J, Liu Y, Wang Y, et al. GALNT14 involves the regulation of multidrug resistance in breast cancer cells[J]. Translational Oncology, 2018, 11(3):786~793. [10] Song L, Linstedt A. Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels.[J]. eLife,2017, 6:e24051. [11] Wu H,He G,Song T, et al. Evaluation of GALNT16 polymorphisms to breast cancer risk in Chinese population[J]. Molecular Genetics and Genomic Medicine,2019,7(8):e848. [12] Fang R, Xu F, Shi H, et al. LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis via modulating GALNT1 activity[J]. Oncogene,2020,39(11):2290~2304. |